164 search results for: Pathophysiology

World Anosmia Awareness Day
On Demand
World Anosmia Awareness Day

Explore our educational resources about loss of smell and the role of type 2 inflammation in CRSwNP, featuring expert insights from Profs. Wytske Fokkens and Joaquim Mullol.

FeNO as a Biomarker for Type 2 Asthma
Pulmonology
FeNO as a Biomarker for Type 2 Asthma
expert video

Dr. Eugene Bleecker presents the utility of FeNO as a biomarker of type 2 inflammation, and its role in the disease burden of asthma.

View more
IgE as a Biomarker for Type 2 Asthma
Pulmonology
IgE as a Biomarker for Type 2 Asthma
expert video

Dr. Jonathan Corren describes the diagnostic, predictive, and prognostic role of IgE as a biomarker of type 2 inflammation in asthma.

View more
Eosinophils as a Biomarker for Type 2 Asthma
Pulmonology
Eosinophils as a Biomarker for Type 2 Asthma
expert video

Dr. Elliot Israel presents the utility of eosinophils as a biomarker of type 2 inflammation and their role in the disease burden of asthma.

View more
Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden
Dermatology
Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden
expert video

In this video from the April 2025 WCPD symposium, Dr Paula Luna discusses the multidimensional disease burden in pediatric patients with AD and the data regarding how early intervention may lead to long-term disease control and a reduced risk of developing non-atopic comorbidities.

View more
From Protective Type 2 Immunity to Aberrant Type 2 Inflammation
Type 2 Inflammation
From Protective Type 2 Immunity to Aberrant Type 2 Inflammation
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares explains how type 2 immunity evolved to protect against parasites, venoms, and toxins, and how its dysregulation can result in aberrant type 2 inflammation underlying multiple chronic inflammatory diseases.

View more
IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in CRSwNP
On Demand
IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in CRSwNP

Dr. Stella Lee and Profs. Peter Hellings and Wytske Fokkens discuss type 2 inflammation, partnering with patients to improve outcomes, and real-world data on biologic effectiveness in CRSwNP.

ADVENT at ERS 2024
On Demand
ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

Join Klaus Rabe, MD, PhD, FERS; Celeste Porsberg, MD, PhD; and Mario Castro, MD, MPH, for a symposium on airway remodeling in severe asthma patients.

ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden
Pulmonology
ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden
expert video

Professor Henrik Watz explores the complex relationship between inflammation and COPD, highlighting its impact on patients' health and overall quality of life.

View more
ADVENT at ERS 2024
On Demand
ERS 2024 | A Breath of Fresh Air: A Greater Understanding of COPD With Type 2 Inflammation

Join experts Henrik Watz, Mona Bafadhel, and Alberto Papi for an educational symposium on the link between underlying drivers of COPD with type 2 inflammation and cumulative patient burden, exploring the role of type 2 cytokines, and current and emerging therapies.

ADVENT at ERS 2024
On Demand
ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management

Engage with experts Klaus Rabe, Stephanie Christenson, and Paola Rogliani in an educational symposium to explore the inflammatory pathways and phenotypes of COPD, investigate the genetic associations of IL-33 and COPD, examine early preclinical findings, and review ongoing research on the role of IL-33 in COPD.

ERS 2025 Enduring Video: Type 2 Severe Asthma “Unplugged”: Reducing Mucus to Improve Long- Term Patient Outcomes
On Demand
ERS 2025 Enduring Video: Type 2 Severe Asthma “Unplugged”: Reducing Mucus to Improve Long- Term Patient Outcomes

Join Drs. Njira Lugogo, Simon Couillard, and Mario Castro for a session exploring the link between pathogenic mucus and impaired lung function in patients with moderate-to-severe asthma and the potential for disease modification with targeted therapy.